Shearman & Sterling represented InRetail Pharma S.A. (the “Company”) in connection with its (i) Rule 144A and Regulation S offering of US$400 million aggregate principal amount of its 5.375% senior notes due 2023 and (ii) Regulation S offering of S/385,800,000 aggregate principal amount of its 6.4375% senior notes due 2025. The Company plans to use the net proceeds from the offerings to partially pay the bridge loan with which it financed the acquisition of Quicorp S.A.
The Company is a leading pharmaceutical platform in the Andean region, with the largest retail pharmacy operation in Peru and one of the largest distribution networks in the Andean region. It operates throughout the pharmaceutical value chain, focusing on retail pharmacies and pharmaceutical distribution and marketing businesses. It also manufactures certain pharmaceutical products.
The Shearman & Sterling team below was supported by international associate Blanca Garcia (New York-Capital Markets).